ReviewNanomaterials (Basel, Switzerland)2016
Nanomaterials for Cardiac Myocyte Tissue Engineering.
Review in Nanomaterials (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Reactive Oxygen Species in Cardiovascular and Hematological Diseases: Mechanisms and Therapeutic Strategies.Cureus · 2026Review
- Progress and prospect of nanotechnology for cardiac fibrosis treatment.Interdisciplinary medicine · 2023Review
- A Review on the Applications of Natural Biodegradable Nano Polymers in Cardiac Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2023Review
- Nanomaterials for Cardiac Tissue Engineering.Molecules (Basel, Switzerland) · 2020Review
- Three-dimensional scaffold-free microtissues engineered for cardiac repair.Journal of materials chemistry. B · 2020Review
- Nanoengineering in Cardiac Regeneration: Looking Back and Going Forward.Nanomaterials (Basel, Switzerland) · 2020Review
- Combining Nanomaterials and Developmental Pathways to Design New Treatments for Cardiac Regeneration: The Pulsing Heart of Advanced Therapies.Frontiers in bioengineering and biotechnology · 2020Review
- The rationale and emergence of electroconductive biomaterial scaffolds in cardiac tissue engineering.APL bioengineering · 2019Review
- Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities.Chemical reviews · 2019Review
- Gold Nanoparticle-Functionalized Reverse Thermal Gel for Tissue Engineering Applications.ACS applied materials & interfaces · 2019Article
- Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases.International journal of nanomedicine · 2018Review
- Covalent Organic Frameworks: From Materials Design to Biomedical Application.Nanomaterials (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their synthesizing introduction to the research community, nanomaterials have infiltrated almost every corner of science and engineering. Over the last decade, one such field has begun to look at using nanomaterials for beneficial applications in tissue engineering, specifically, cardiac tissue engineering. During a myocardial infarction, part of the cardiac muscle, or myocardium, is deprived of blood. Therefore, the lack of oxygen destroys cardiomyocytes, leaving dead tissue and possibly resulting in the development of arrhythmia, ventricular remodeling, and eventual heart failure. Scarred cardiac muscle results in heart failure for millions of heart attack survivors worldwide. Modern cardiac tissue engineering research has developed nanomaterial applications to combat heart failure, preserve normal heart tissue, and grow healthy myocardium around the infarcted area. This review will discuss the recent progress of nanomaterials for cardiovascular tissue engineering applications through three main nanomaterial approaches: scaffold designs, patches, and injectable materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.